Market revenue in 2023 | USD 248.8 million |
Market revenue in 2030 | USD 650.4 million |
Growth rate | 14.7% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.89% in 2023. Horizon Databook has segmented the China immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
In China, three types of biomarkers are mainly used for the diagnosis of neurodegenerative diseases, such as Alzheimer’s: Cerebrospinal fluid (CSF) Biomarkers: The widely used and recommended CSF biomarkers are CSF-tau and Aβ (Aβ42, Aβ40).
CSF tau has a lower accuracy rate than Aβ biomarkers because tau-mediated neuronal damage occurs after AB accumulation. Blood Biomarkers: Some of the blood biomarkers include Aβ, Aβ42, Aβ42/40, p-tau, beta-secretase, neuro exosomal synaptic proteins, and neurofilament light chain.
The availability of biomarkers in small quantities in blood makes it harder for researchers to measure and offer low sensitivity. Thus, the focus of research in this field is mainly on developing better diagnostic technologies such as immune-infrared sensors and ELISA kits to measure the blood biomarker for diagnosis.
Horizon Databook provides a detailed overview of country-level data and insights on the China immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into China immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account